Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 29, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the "Grant Date") that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 14 individuals hired by Sarepta in November 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
馬薩諸塞州劍橋-（BUSINESS WIRE）-2024年11月29日-領先的罕見病精準遺傳醫學企業sarepta therapeutics公司（納斯達克股票代碼：SRPT）向其於2024年11月29日（「授予日期」）僱傭的14名員工授予了股權獎勵，這些獎勵此前已獲得了董事會薪酬委員會在sarepta的2024年僱傭開始激勵計劃下的批准，作爲對這些員工就職的重要誘因。這些股權獎勵是根據納斯達克上市規則5635(c)(4)批准的。
The employees received in the aggregate 8,040 restricted stock units ("RSUs"). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee's continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta's common stock.
員工們共收到了8,040個限制性股票單位（「RSUs」）。每年在授予日期的每個週年，這些RSUs中的四分之一將獲得一次激勵，使得每名員工獲得的RSUs在授予日期的第四週年將完全獲得激勵，在每種情況下，前提是該僱員在該激勵日期依然與sarepta公司保持僱傭關係。員工們沒有收到買入sarepta公司普通股的期權。
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
關於Sarepta Therapeutics
Sarepta緊急任務：爲破壞生活和砍短未來的罕見疾病而工程化精準基因醫學。我們在杜興肌肉萎縮症（DMD）和肢帶肌肉萎縮症（LGMD）方面擁有領先地位，目前正在開發超過40個處於不同階段的項目。我們龐大的研發管線，由多平台精準基因醫學引擎驅動，涵蓋基因療法、RNA和基因編輯。欲了解更多信息，請訪問 鏈接 並關注我們的 領英，X（曾爲Twitter），Instagram和Facebook帳戶。
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at . We encourage investors and potential investors to consult our website regularly for important information about us.
信息的互聯網發佈
我們會定期在網站的「投資者」版塊發佈可能對投資者重要的信息。我們鼓勵投資者和潛在投資者定期查閱我們的網站以了解我們的重要信息。
Source: Sarepta Therapeutics, Inc.
來源：Sarepta Therapeutics，Inc。
View source version on businesswire.com:
在businesswire.com上查看源版本：
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
投資者聯繫人：
Ian Estepan，617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
媒體聯繫：
Tracy Sorrentino，617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
來源：Sarepta Therapeutics，Inc。
譯文內容由第三人軟體翻譯。
